Legend Biotech (LEGN) Receivables (2019 - 2025)

Legend Biotech's Receivables history runs 7 years deep, the most recent figure standing at $13.1 million for Q4 2025.

• Quarterly Receivables fell 88.37% year-over-year to $13.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $13.1 million (down 88.37% YoY) and the FY2025 annual result came in at $13.1 million, down 88.37% from the prior year.
• Receivables was $13.1 million for Q4 2025 at Legend Biotech, up from $1.2 million in the prior quarter.
• Across five years, Receivables topped out at $159.7 million in Q1 2025 and bottomed at $15000.0 in Q2 2021.
• A 5-year average of $49.0 million and a median of $50.5 million in 2022 frame the typical range for Receivables.
• Annual changes were most pronounced in 2023 — Receivables plunged 99.89% — and 2024, when it soared 122966.07%.
• Legend Biotech's Receivables stood at $51.2 million in 2021, then plunged by 97.97% to $1.0 million in 2022, then jumped by 5109.83% to $54.1 million in 2023, then soared by 108.32% to $112.7 million in 2024, then tumbled by 88.37% to $13.1 million in 2025.
• Business Quant data shows LEGN's Receivables at $13.1 million in Q4 2025, $1.2 million in Q3 2025, and $27.6 million in Q2 2025.